2024-05-03, Fri.

Top Stories       Business       Culture & Life       Science & Technology       World

Lecture

Notification

 

NEWS > World


The World Health Organization Includes the Cardiovascular Polypill Developed by the Spanish National Centre for Cardiovascular Research and Ferrer in

Date: 2023-08-03

MADRID-- August 03, 2023 -- The cardiovascular polypill developed by the Spanish National Centre for Cardiovascular Research (CNIC) and Ferrer has been included by the World Health Organization (WHO) in its List of Essential Medicines[1].

This cardiovascular polypill includes three active ingredients (acetylsalicylic acid, ramipril and atorvastatin) and has been proven to be effective in preventing cardiovascular events after a heart attack, reducing mortality from cardiovascular causes by 33%. This was evidenced by the SECURE[2] study, with results published in August 2022 in the New England Journal of Medicine[3] (NEJM).

“The SECURE results showed, for the first time, that the cardiovascular polypill developed by the CNIC and Ferrer achieves clinically relevant reductions in recurrent cardiovascular events in patients who have suffered a myocardial infarction,” said Dr. Valentín Fuster, principal investigator of the study, General Director of the CNIC, President of Mount Sinai Heart and Physician-in-Chief of Mount Sinai Hospital, New York.

As stated in the WHO report, “essential medicines are those that satisfy the priority health care needs of a population. They are intended to be available in functioning health systems at all times, in appropriate dosage forms, of assured quality and at prices individuals and health systems can afford.”

According to Oscar Pérez, Chief Marketing, Market Access and Business Development Officer at Ferrer, “the 33% reduction in cardiovascular mortality demonstrates the efficacy of treatment with Trinomia[4] compared to standard treatment. The inclusion of this therapeutic solution in the WHO's List of Essential Medicines confirms our aim to make a positive impact in society and is an important step in our mission to bring significant and differential value to people with cardiovascular disease.”

Currently, the cardiovascular polypill developed by the CNIC and Ferrer is marketed in 25 countries and the feasibility of extending its distribution to additional territories, including the United States, is under analysis.



 to the Top List of News

WEF Special Meeting Concludes in Riyadh With World Leaders Calling for Clear, Irreversible Path to Peace and Prosperity as Top Global Priority
Geopolitical Stability, Inclusive Growth, Energy Security Under Spotlight in Riyadh at World Economic Forum Special Meeting
The 2024 Japan Prize Award Ceremony Is Held with Their Majesties the Emperor and Empress of Japan in Attendance
Newmont Publishes 2023 Sustainability Report and 2023 Tax & Royalties Report
[Earth Day with LG] Celebrating Sustainability and Environmental Stewardship with Earth Day Fair
Saudi Arabia Highlights Investment Initiatives in Tourism at International Hospitality Investment Forum
Nominations open for The MIDORI Prize for Biodiversity 2024

 

Innovation Meets Regulation: International Webinar Explored Effective ...
Worldwide Anti-Smoking Policies Charted in Comprehensive Index
Mary Kay Inc. Spearheads Ocean Conservation Efforts at the 11th Annual...
Dalberg Awarded 5-Year Contract to Strengthen United States Agency for...
Socialization Dinner for Ambassadors of APO Members and Steering Commi...
United for Bitcoin : 20+ Crypto Organizations Join Global Bitcoin Emoj...
First Doses of BRUKINSA provided to Patients with Chronic Lymphocytic ...
From Commitment to Action: Mary Kay Releases Overview of Transformativ...
Kinaxis Teams Up with Non-Profit Leaders to Accelerate Social and Envi...
Japan Hosted a Conference to Boost Ukraine¡¯s Economic Growth and Reco...

 

 

60, Gamasanro 27gil, Guro-gu, Seoul, Korea, e-mail: news@newsji.com

Copyright, NEWSJI NETWORK.